M&A

The acquisition will allow Prange Group and Adragos Pharma to expand their global presence, as well as adding significant capacity for sterile liquid manufacturing. Fresenius Kabi is expected to come to a long-term supply agreement for the products manufactured at the site.

The site, in Halden, Norway, is one of the largest and most advanced sterile production facilities in Northern Europe, producing products such as IV bags, ampoules, blow-fill-seal technology, along with other pharmaceutical dosage forms.

Otto Prange, chairman of the Prange Group, commented: “Our collaboration with Fresenius Kabi is a strategic step that resonates with Prange Group’s commitment to quality and reliability in supplying our customers and in caring for patients globally. Through our partnership with Adragos Pharma, we are set to enhance the potential of the Halden site, which is a testament to the dedication of Halden’s workforce. Recognising the value of our employees, we are dedicated to fostering their expertise, ensuring that the legacy and integrity of the site continue to thrive.”

Dr Andreas Raabe, chief executive officer of Adragos Pharma, added: “The inclusion of the Halden site into Adragos Pharma’s network is a fantastic addition to our network. Halden has a broad range of technologies and offers considerable expansion space that allows us to tailor our services to the specific needs of our customers. We will be positioning the site as one of Europe’s premier sterile production facilities.”

Dr Hans-Christian Meyer, senior vice president operations at Fresenius Kabi, stated: “This divestiture reflects our strategic decision to optimise our network and focus on our core areas of expertise. We are confident that the Prange Group together with Adragos Pharma are the right partners to carry forward the legacy of the Halden site.”